Company / Income Tax
BioMarin Pharmaceutical Income Tax History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Income Tax
$133.6M
FY2025
5-year range
-$11.3M / $133.6M
FY2021-FY2025
Trend
+16.3%
vs FY2024
Sector context
#19 of 204
Health Care
What the data says
Among 204 Health Care companies, BioMarin Pharmaceutical is in the bottom 9% for income tax. Income Tax has increased for 5 consecutive years, from -$903M in FY2020 to $134M in FY2025.
Based on SEC 10-K filings.
$134M in FY2025 with a 3-year CAGR of +155.4%. Top quartile in the Health Care sector.
Increased from $21M to $134M over the past 2 years.
Health Care sector context is included.
Income Tax over time
Growth rates
- 3-Year CAGR
- +155.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 204This company $133.6M Sector average $118.7M
▼
+12.5% above sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's income tax has grown for 5 consecutive years.
- 3-year CAGR of +155.4%, indicating consistent growth.
- In FY2025, income tax increased 16.3% year-over-year.
- Ranks #19 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Income TaxValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $133.6M | +16.3% |
| FY2024 | $114.9M | +449.3% |
| FY2023 | $20.9M | +161.0% |
| FY2022 | $8.0M | +171.1% |
| FY2021 | -$11.3M | +98.8% |
| FY2020 | -$903.0M | -1172.5% |
| FY2019 | -$71.0M | -8.4% |
| FY2018 | -$65.5M | -180.7% |
| FY2017 | $81.2M | +140.4% |
| FY2016 | -$200.8M | -1276.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026